Clinical trial
Open access
Jul 2026
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
Setmelanotide led to significantly greater reductions in BMI and hunger than placebo at 52 weeks among participants 4 to 66 years of age with acquired hypothalamic obesity.
J. Miller, H. V. van Santen, Susan A. Phillips et al.
· New England Journal of Medic... · 6 citations
· ⚡2